Pegaptanib
- Generic Name
- Pegaptanib
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 222716-86-1
- Unique Ingredient Identifier
- 3HP012Q0FH
- Background
Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability.
Pegaptanib was granted FDA approval on 17 September 2004.
- Indication
For the treatment of neovascular (wet) age-related macular degeneration.
- Associated Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
Macugen for Histoplasmosis
- Conditions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2006-10-27
- Lead Sponsor
- Barnes Retina Institute
- Target Recruit Count
- 24
- Registration Number
- NCT00272766
- Locations
- 🇺🇸
Barnes Retina Institute, St. Louis, Missouri, United States
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
- Conditions
- Interventions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 111
- Registration Number
- NCT00242580
- Locations
- 🇺🇸
Novartis Investigational Site, Austin, Texas, United States
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2011-05-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT00239928
- Locations
- 🇯🇵
Pfizer Investigational Site, Kyoto, Japan
Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT00150202
- Locations
- 🇯🇵
Pfizer Investigational Site, Kyoto, Japan
Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
- Conditions
- First Posted Date
- 2004-07-26
- Last Posted Date
- 2007-01-19
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT00088283
- Locations
- 🇺🇸
Jules Stein Institute, Los Angeles, California, United States
🇺🇸Orange County Retina Associates, Santa Ana, California, United States
🇺🇸Cumberland Valley Retina Center, Hagerstown, Maryland, United States
Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
- Conditions
- First Posted Date
- 2004-07-22
- Last Posted Date
- 2005-08-30
- Lead Sponsor
- Eyetech Pharmaceuticals
- Registration Number
- NCT00088192
- Locations
- 🇺🇸
Eye Foundation of Kansas City, Kansas City, Missouri, United States
🇺🇸The Eye Center of Concord, Concord, New Hampshire, United States
🇺🇸Retina Associates of Cleveland Inc., Lakewood, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.